ProQR to Present at the 2015 Leerink Global Healthcare Conference
LEIDEN, The Netherlands, Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, today announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 2:40 pm EST in New York, NY, USA.
The live and archived webcast of the fireside chat will be accessible from the "Investor Relations" section of ProQR's website (www.proqr.com). The archived webcast will be available for 30 days following the presentation date.
About ProQR
ProQR is an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We believe this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.
ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 650 464 9879
ir@proqr.com
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494
gschweitzer@macbiocom.com
